To set up an effective analysis of Vertex Pharmaceuticals' share price, we suggest you learn a little more about this company and its economic environment. In this article, we will provide you with a variety of useful information for your forecasts, including detailed information about the company's activities, its main competitors in the market and its most recent partnerships. We will also give you a few tips for a successful fundamental analysis of this stock.
First of all, the research and development activities carried out by this group will be closely monitored, with tests and clinical trials on drugs and treatments that are likely to be marketed and subject to patent applications.
Legislation and regulatory developments in the area of health and treatment are of course also part of the elements that you should watch out for, as they may affect the profitability of this group.
We will also keep an eye on what is happening at Vertex Pharmaceuticals' major competitors with competing patents, strategic mergers and other major events.
It goes without saying that the company's quarterly and annual results publications will have to be taken into consideration, as will the strategic development plans on which the company regularly reports.
We now invite you to discover a little more information about Vertex Pharmaceuticals and its activities. Indeed, it is essential that you understand how this group generates its revenues before speculating on its share price.
The Vertex Pharmaceuticals group is a US company specialising in the research, development and marketing of micro-molecular drugs, particularly for the treatment of certain cancers, viral diseases, inflammatory diseases and autoimmune diseases.
In order to better understand Vertex's activities, they can be divided into different divisions according to the share of turnover they generate :
The geographical distribution of this group's revenues is also interesting to know and it should be noted that Vertex achieves 73.6% of its turnover in the United States, 21.3% in Europe and 5.1% in the rest of the world.
Although the Vertex Pharmaceuticals group is currently one of the leaders in its sector, particularly in the US market, it is of course not the only one in the sector and faces relatively strong competition. Here are its main opponents:
This American pharmaceutical company founded in 1888 is a major pharmaceutical industry in the United States and currently employs more than 90,000 people.
This other American company specialising in pharmaceutical research is active in the development of therapeutic drugs to treat rheumatoid arthritis, psoriasis, Crohn's disease, thyroid problems, Parkinson's disease, HIV or certain complications of cystic fibrosis, low testosterone levels or complications of kidney disease.
This American pharmaceutical laboratory specialises in ophthalmology, neurology and dermatology products. It is known for having created Botox.
This company created in 1980 is a leader in the medical biotechnology industry and is an American company based in California.
Biogen is a US company dating from 2003 and created by the merger of two world leaders in biotechnology, namely Biogen Inc and IDEC Pharmaceuticals Corporation.
This other American pharmaceutical group is currently one of the largest in its sector in terms of turnover.
Finally, the last serious competitor of Vertex Pharmaceuticals is the American group Gilead Sciences which specialises in pharmaceuticals and develops similar products.
Although there are unfortunately few examples of recent partnerships on the part of the Vertex Pharmaceuticals group, we can however talk here about an agreement recently concluded with the Australian government, the details of which we will give you here.
In 2018, Vertex Pharmaceuticals announced an agreement with the Australian government to reimburse ORKAMBI for 6-year-olds with cystic fibrosis who have two copies of the F505del mutation in the transmembrane conductance regulator gene for cystic fibrosis. As a result of this agreement, this treatment will be included in the drug plan from 1 October this year 2018 and following a positive recommendation from Australia's Pharmaceutical Benefits Advisory Committee. Indeed, access to the future treatment being discussed here is being established as part of this process.
It goes without saying that future partnerships are likely to occur in the coming months or years.
If you are interested in the shares of the American group Vertex Pharmaceuticals, you can trade this stock online without any problem via a CFD trading platform. These Contracts for Difference (CFDs) allow you to bet on the rise or fall of many international stocks, including US stocks such as Vertex Pharmaceuticals.
As mentioned earlier in this article, the clinical trials conducted by Vertex Pharmaceuticals Group to develop and validate new treatments are important elements to follow. As part of its policy of transparency, the group provides access to this information and publishes the results of its various research projects directly on its official website, where you can consult them freely.
As part of your technical analysis of the Vertex Pharmaceuticals share price, you will take care to study certain indicators in particular. This is particularly the case for technical trend indicators and volatility indicators. Pivotal points, support and resistance levels can also be used to take a position at the best time, i.e. at the start of a trend or when it is turning up or down.
